Pharmaceutical Industry News 24 December 2025

Corcept stock slides nearly 9% as FDA decision deadline arrives — what’s driving CORT today

NEW YORK, December 30, 2025, 13:14 ET — Regular session Corcept Therapeutics Inc shares fell 8.9% to $72.72 in early afternoon Nasdaq trading on Tuesday, after touching a session low of $72.26. The stock was last down $7.10 from Monday’s

30 December 2025

Biotech News·FDA Approvals·Investment Analysis·Pharmaceutical Industry·Stock Market

Praxis Precision Medicines (PRAX) stock jumps 13% after FDA breakthrough designation for tremor drug

NEW YORK, December 30, 2025, 00:52 ET — Market closed. Praxis Precision Medicines shares climbed about 13% in Monday’s session, last trading at $304.58, after the company said U.S. regulators granted Breakthrough Therapy Designation for its experimental essential tremor treatment.

30 December 2025

Biotechnology·FDA Approvals·Investment Insights·Pharmaceutical Industry·Stock Market News

Eli Lilly Stock (LLY) News Today: What Investors Should Watch Before Monday’s Open After GLP‑1 Pill Breakthroughs, Pricing Signals, and Fresh Deal Headlines

NEW YORK, Dec. 28, 2025, 10:33 a.m. ET — Market Closed (Weekend) Eli Lilly and Company (NYSE: LLY) heads into the final two trading days of 2025 with U.S. markets closed for the weekend and investors weighing a familiar mix

28 December 2025

Company Updates·Financial Analysis·Investment Tips·Pharmaceutical Industry·Stock Market News

AbbVie Stock (ABBV) Holds Near $230 as Year-End “Santa Rally” Takes Shape; Dividend Boost, Legal Headlines and 2026 Outlook in Focus

NEW YORK, Dec. 27, 2025, 5:15 PM ET — Market closed. AbbVie Inc. (NYSE: ABBV) heads into the weekend with Wall Street shut and year-end positioning in full swing, after a quiet, post-holiday session on Friday left major U.S. indexes

27 December 2025

Dividends·Financial Analysis·Investment News·Pharmaceutical Industry·Stock Market

Pfizer Stock (PFE) Update: Shares Hold Near $25 Into Year-End as Investors Weigh 2026 Guidance, Dividend, and Pipeline Catalysts

NEW YORK, Dec. 27, 2025, 3:07 p.m. ET — Market closed Pfizer Inc. (NYSE: PFE) is heading into the final trading days of 2025 with its stock still anchored in the mid-$20s, a range that has increasingly defined sentiment around

27 December 2025

Dividend Stocks·Investment Strategies·Pfizer News·Pharmaceutical Industry·Stock Market

Wave Life Sciences (WVE) Stock Today: Obesity Drug Catalyst, $402.5M Financing, and What Investors Are Watching Next

New York, Dec. 26, 2025 (10:08 a.m. ET) — Wave Life Sciences Ltd. (NASDAQ: WVE) is trading at $18.12, down about 0.74% in the late morning session. The move comes while biotech is broadly softer—SPDR S&P Biotech ETF (XBI) is

26 December 2025

Biotech News·Financial Analysis·Investment Strategies·Pharmaceutical Industry·Stock Market

Eli Lilly (LLY) Stock After Hours Today (Dec. 25, 2025): Holiday Pause, GLP‑1 Catalysts, and What to Watch Before the Market Opens Dec. 26

Updated: Thursday, December 25, 2025 — U.S. exchanges are closed for Christmas Day, so the latest “after-hours” read for Eli Lilly and Company (NYSE: LLY) reflects trading following Wednesday’s holiday-shortened session. New York Stock Exchange Eli Lilly shares finished the

25 December 2025

After Hours Trading·Pharmaceutical Industry·Stock Market News

Bristol-Myers Squibb (BMY) Stock News, Forecasts and Outlook as of Dec. 25, 2025: Breyanzi FDA Win, Eliquis Medicaid Deal, and 2026 Catalysts

Bristol-Myers Squibb Company (NYSE: BMY) heads into Dec. 25, 2025 with its stock anchored in the mid-$50s — and with investors juggling two competing storylines: With U.S. markets effectively pausing for the holiday, the most recent available NYSE quote showed

25 December 2025

FDA Approvals·Financial Forecasts·Investment Analysis·Pharmaceutical Industry·Stock Market

Bristol-Myers Squibb (BMY) Stock After Hours on Dec. 24, 2025: Key News, Forecasts, and What to Watch Before the Next Market Open

Bristol-Myers Squibb Company (NYSE: BMY) ended the Christmas Eve session with a modest gain—and then stayed largely quiet in after-hours trading as U.S. markets wrapped an early close and investors looked ahead to the next full session on Friday, Dec.

25 December 2025

Financial News·Investing·Market Analysis·Pharmaceutical Industry·Stock Market

Omeros (OMER) Stock Surges After Hours on Dec. 24, 2025 After FDA Approves Yartemlea — What to Know Before the Next Market Open

Omeros Corporation (NASDAQ: OMER) is ending Christmas Eve 2025 as one of the market’s most volatile and news-driven movers after the U.S. Food and Drug Administration approved the company’s first commercial product — a moment investors have waited years to

24 December 2025

Biotech News·FDA Approvals·Investing·Pharmaceutical Industry·Stock Market

Merck (MRK) Stock After Hours Today: Shares Hit a New 52-Week High on Dec. 24, 2025 — What to Know Before U.S. Markets Reopen

NEW YORK — December 24, 2025: Merck & Co., Inc. (NYSE: MRK) ended a holiday-shortened Christmas Eve session near $106.45, up about 1.3% on the day, and held close to those levels in thin after-hours trading. MarketBeat The move capped

24 December 2025

Financial Analysis·Investing·Market News·Pharmaceutical Industry·Stock Market

Edgewise Therapeutics Stock (EWTX) Jumps on EDG-7500 CIRRUS-HCM Update: Dec. 24, 2025 News, Analyst Forecasts, and Key Catalysts

Edgewise Therapeutics, Inc. (NASDAQ: EWTX) stock surged in intraday trading on Wednesday, December 24, 2025, after the company released a fresh update on EDG-7500, its investigational therapy for hypertrophic cardiomyopathy (HCM). By late morning, shares were trading around $26.37—up roughly

24 December 2025

Analyst Forecasts·Biotech News·Investment Strategies·Pharmaceutical Industry·Stock Market

Pharmaceutical Industry News 24 December 2025 - 30 December 2025